Core 3 - Epigenomics Core

核心 3 - 表观基因组学核心

• 批准号: 10555737
• 负责人: Charles B Epstein
• 金额: $ 39.19万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-12-01 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10555737
• 关键词: ATAC-seq; Adopted; Algorithms; Bar Codes; Cell Count; Cells; ChIP-seq; Chromatin; Chromatin Structure; Clinical; Clinical Trials; Code; Data; Development; Diagnosis; Distal; Enhancers; Epigenetic Process; Gene Expression; Gene Expression Regulation; Genetic Enhancer Element; Genomics; Goals; Maps; Methods; Mission; Modification; Molecular; Multiple Myeloma; Oncogenic; Physical condensation; Procedures; RNA; Regulatory Element; Relapse; Sampling; Standardization; Therapeutic; Time; Transcript; Untranslated RNA; Variant; Work; XCL1 gene; cancer genomics; cofactor; epigenomics; histone modification; improved; indexing; innovation; multimodal data; multiple omics; neoplastic cell; new therapeutic target; participant enrollment; pre-clinical; programs; transcription factor; transcriptomics; tumor

Project Summary – Core 3 – Epigenomics Core Broad Institute The overall goal of the core is to study the key features of epigenetic features in myeloma and improve our understanding of global gene regulation to deploy novel therapeutics that target key epigenomic factors. Cells and cell states can be defined by their gene expression programs, and tumor cells commonly have deregulated gene expression programs. This core will perform epigenomic analyses on clinical samples from Projects 1 as well as preclinical samples in Project 2, 3 and 4 at bulk and single cell level. Specifically, samples will be obtained from patients enrolled on the previous clinical trial (IFM/DFCI 2009) and the newer IFM-2020-02 trial (evaluating an MRD-based therapeutic algorithms at time of diagnosis and at relapse) in Project 1. In each case, tumor cells will be isolated in Core 2 using well established procedures. This core will perform analysis for epigenetic regulatory factors. The core has capabilities to perform ATAC-seq, MINT ChIP-seq using low cell number (5000 cells; van Galen et al, Molecular Cell 2016 Jan;61(1):1-11), perform single-cell multi-omics (Ma et al, Cell, 2020, 183, 1103–1116.e20) as well as adopt innovative variations specifically needed to answer questions. The core will help with analysis of the generated data and accurately chart maps of epigenetic modifications and related chromatin structures in myeloma. It will work with Core 5 to help integrate these results with other genomic correlates.

项目摘要 – 核心 3 – 表观基因组学核心 Broad Institute 核心的总体目标是研究骨髓瘤表观遗传特征的关键特征，并提高我们的研究水平。 了解全球基因调控，以部署针对关键表观基因组细胞的新疗法。 细胞状态可以通过它们的基因表达程序来定义，肿瘤细胞通常已经失调 该核心将对项目 1 的临床样本进行表观基因组分析。 以及项目2、3和4中的临床前样品，具体而言，将获得批量和单细胞水平的样品。 来自先前临床试验 (IFM/DFCI 2009) 和较新的 IFM-2020-02 试验（评估 项目 1 中基于 MRD 的治疗算法（诊断时和复发时）。在每种情况下，肿瘤细胞 将使用完善的程序在核心 2 中进行分离，该核心将进行表观遗传分析。 核心具有使用低细胞数（5000）执行 ATAC-seq、MINT ChIP-seq 的能力。 细胞；van Galen 等人，Molecular Cell 2016 Jan；61(1):1-11)，进行单细胞多组学（Ma 等人，Cell，2020， 183, 1103–1116.e20) 以及采用回答核心问题所需的创新变体。 将有助于分析生成的数据并准确绘制表观遗传修饰和相关图谱 它将与 Core 5 合作，帮助将这些结果与其他基因组整合。 相关性。